219 related articles for article (PubMed ID: 34788094)
1. Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models.
Singh S; Quarni W; Goralski M; Wan S; Jin H; Van de Velde LA; Fang J; Wu Q; Abu-Zaid A; Wang T; Singh R; Craft D; Fan Y; Confer T; Johnson M; Akers WJ; Wang R; Murray PJ; Thomas PG; Nijhawan D; Davidoff AM; Yang J
Sci Adv; 2021 Nov; 7(47):eabj5405. PubMed ID: 34788094
[TBL] [Abstract][Full Text] [Related]
2. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A; Sikka A; Yogev O; Herendi L; Balcells C; Ma Y; Poon E; Eckold C; Valbuena GN; Xu Y; Liu Y; da Costa BM; Gruet M; Wickremesinghe C; Benito A; Kramer H; Montoya A; Carling D; Want EJ; Jamin Y; Chesler L; Keun HC
Nat Commun; 2022 Mar; 13(1):1380. PubMed ID: 35296644
[TBL] [Abstract][Full Text] [Related]
3. Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Ting TC; Goralski M; Klein K; Wang B; Kim J; Xie Y; Nijhawan D
Cell Rep; 2019 Nov; 29(6):1499-1510.e6. PubMed ID: 31693891
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE; Xie L; Srinivas H; Shu W; Burke A; Be C; Zhao J; Godbole A; King D; Karki RG; Hornak V; Xu F; Cobb J; Carte N; Frank AO; Frommlet A; Graff P; Knapp M; Fazal A; Okram B; Jiang S; Michellys PY; Beckwith R; Voshol H; Wiesmann C; Solomon JM; Paulk J
Nat Chem Biol; 2020 Jan; 16(1):15-23. PubMed ID: 31819272
[TBL] [Abstract][Full Text] [Related]
5. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T; Goralski M; Gaskill N; Capota E; Kim J; Ting TC; Xie Y; Williams NS; Nijhawan D
Science; 2017 Apr; 356(6336):. PubMed ID: 28302793
[TBL] [Abstract][Full Text] [Related]
6. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Lu J; Jiang H; Li D; Chen T; Wang Y; Pu Z; Xu G
J Proteome Res; 2021 Sep; 20(9):4462-4474. PubMed ID: 34420308
[TBL] [Abstract][Full Text] [Related]
7. RNA-binding motif protein 39 (RBM39): An emerging cancer target.
Xu Y; Nijhuis A; Keun HC
Br J Pharmacol; 2022 Jun; 179(12):2795-2812. PubMed ID: 33238031
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.
Du X; Volkov OA; Czerwinski RM; Tan H; Huerta C; Morton ER; Rizzi JP; Wehn PM; Xu R; Nijhawan D; Wallace EM
Structure; 2019 Nov; 27(11):1625-1633.e3. PubMed ID: 31693911
[TBL] [Abstract][Full Text] [Related]
9. Insights on the biological functions and diverse regulation of RNA-binding protein 39 and their implication in human diseases.
Eléouët M; Lu C; Zhou Y; Yang P; Ma J; Xu G
Biochim Biophys Acta Gene Regul Mech; 2023 Mar; 1866(1):194902. PubMed ID: 36535628
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Xu Y; Spear S; Ma Y; Lorentzen MP; Gruet M; McKinney F; Xu Y; Wickremesinghe C; Shepherd MR; McNeish I; Keun HC; Nijhuis A
Cell Rep; 2023 Oct; 42(10):113307. PubMed ID: 37858464
[TBL] [Abstract][Full Text] [Related]
11. Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Pogacar Z; Groot K; Jochems F; Dos Santos Dias M; Mulero-Sánchez A; Morris B; Roosen M; Wardak L; De Conti G; Velds A; Lieftink C; Thijssen B; Beijersbergen RL; Bernards R; Leite de Oliveira R
Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35534224
[TBL] [Abstract][Full Text] [Related]
12. The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1.
Lu J; Li D; Jiang H; Li Y; Lu C; Chen T; Wang Y; Wang X; Sun W; Pu Z; Qiao C; Ma J; Xu G
J Biol Chem; 2023 Apr; 299(4):103025. PubMed ID: 36805336
[TBL] [Abstract][Full Text] [Related]
13. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.
Faust TB; Yoon H; Nowak RP; Donovan KA; Li Z; Cai Q; Eleuteri NA; Zhang T; Gray NS; Fischer ES
Nat Chem Biol; 2020 Jan; 16(1):7-14. PubMed ID: 31686031
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor.
Jablonowski C; Quarni W; Singh S; Tan H; Bostanthirige DH; Jin H; Fang J; Chang TC; Finkelstein D; Cho JH; Hu D; Pagala V; Sakurada SM; Pruett-Miller SM; Wang R; Murphy A; Freeman K; Peng J; Davidoff AM; Wu G; Yang J
bioRxiv; 2023 Nov; ():. PubMed ID: 37425900
[TBL] [Abstract][Full Text] [Related]
15. Aryl Sulfonamides Induce Degradation of Aryl Hydrocarbon Receptor Nuclear Translocator through CRL4
Kim SA; Jo SH; Cho JH; Yu MY; Shin HC; Kim JA; Park SG; Park BC; Kim S; Kim JH
Mol Cells; 2020 Nov; 43(11):935-944. PubMed ID: 33168788
[TBL] [Abstract][Full Text] [Related]
16. Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation.
Coomar S; Mota P; Penson A; Schwaller J; Abdel-Wahab O; Gillingham D
Mol Cancer Res; 2023 Aug; 21(8):768-778. PubMed ID: 37255411
[TBL] [Abstract][Full Text] [Related]
17. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate.
Jia X; Pan L; Zhu M; Hu H; Zhai L; Liu J; Hu M; Liu B; Tan M
J Proteomics; 2020 Jan; 210():103545. PubMed ID: 31626998
[TBL] [Abstract][Full Text] [Related]
18. Indisulam exerts anticancer effects via modulation of transcription, translation and alternative splicing on human cervical cancer cells.
Dou Z; Zhang X; Su W; Zhang T; Ye F; Zhao D; Chen X; Li Q; Zhang H; Di C
Am J Cancer Res; 2023; 13(7):2922-2937. PubMed ID: 37559979
[TBL] [Abstract][Full Text] [Related]
19. The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
Melnyk JE; Steri V; Nguyen HG; Hann B; Feng FY; Shokat KM
Bioorg Med Chem; 2020 Oct; 28(20):115712. PubMed ID: 33069070
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
